Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.50 |
| ▸ | GBA1 | P04062 | 1/20 | 0.50 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13090657 | 1.00 | FUCA1 (0.50) | FUCA1GBA1S1PR5NPC1RAB9A | |
| SCHEMBL440211 | 0.88 | GBA1 (0.66) | FUCA1GBA1S1PR5 | |
| SCHEMBL403643 | 0.88 | GBA1 (0.66) | FUCA1GBA1S1PR5 | |
| SCHEMBL2454394 | 0.88 | GBA1 (0.66) | FUCA1GBA1S1PR5 | |
| SCHEMBL13090653 | 0.86 | GBA1 (0.49) | FUCA1GBA1S1PR5NPC1RAB9A | |
| SCHEMBL13090652 | 0.85 | GBA1 (0.42) | FUCA1GBA1S1PR5RORC | |
| SCHEMBL13100637 | 0.84 | GBA1 (0.45) | FUCA1GBA1S1PR5RAB9AALDH1A1 | |
| SCHEMBL8171730 | 0.81 | FUCA1 (0.53) | FUCA1S1PR5S1PR1 | |
| SCHEMBL500382 | 0.81 | GBA1 (0.58) | FUCA1GBA1S1PR5S1PR1 | |
| SCHEMBL500383 | 0.81 | GBA1 (0.58) | FUCA1GBA1S1PR5S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940766-B2 | Methods for preventing and/or treating lysosomal storage disorders | AMICUS THERAPEUTICS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2416655-B1 | METHODS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMICUS THERAPEUTICS INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8304429-B2 | Methods for preventing and/or treating degenerative disorders of the central nervous system | AMICUS THERAPEUTICS, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| EP-2416656-A1 | METHODS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS | Amicus Therapeutics, Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| EP-2416655-A1 | METHODS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | Amicus Therapeutics, Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| US-20100261753-A1 | METHODS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMICUS THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100260740-A1 | METHODS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS | AMICUS THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| WO-2010118282-A1 | METHODS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMICUS THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010118283-A1 | METHODS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS | AMICUS THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261753-A1 | METHODS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | SNCA, BDNF, PARK7 | FUCA1 727/4885GBA1 71/4885S1PR5 72/4885 |
| US-20100260740-A1 | METHODS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS | GBA1, GAA, MAN2B1 | FUCA1 156/4885GBA1 1/4885S1PR5 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.